Last reviewed · How we verify
Triamcinolone Acetonide Injectable Suspension
At a glance
| Generic name | Triamcinolone Acetonide Injectable Suspension |
|---|---|
| Also known as | Zilretta, Zilretta Injectable Product, ZILRETTA |
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata (NA)
- Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery (PHASE2)
- A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (PHASE2)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- Efficacy of Intramuscular Steroid Injection for Chronic Cough. (EARLY_PHASE1)
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (PHASE4)
- Biological Response to Platelet-rich Plasma and Corticosteroid Injections (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: